Hormonal health focused hardware startup Inne has raised $8.8M in Series A+ funding led by DSM Ventures. Other investors in this recent round include Borski Fund, Calm Storm Ventures as well as a number of angels, including Wise’s Taavet Hinrikus, Crista Galli Ventures’ Dr. Fiona Pathiraja and Trivago’s Rolf Schromgens. The company closed an $8.8M Series A back in 2019. According to Techcrunch, who shared an interview with Founder & CEO Eirini Rapti, the new funds will be used to “stock up on raw materials and retool its production line to unplug any remaining production bottlenecks” and R&D. Today the company’s signature mini-lab, a saliva-based hormone-testing device, can be used for cycle & fertility tracking. Inne is currently seeking approval as a digital contraceptive and also plans to add additional tests like one for cortisol, the stress hormone linked to both athletic performance and a number of women’s health conditions.
The company, that has only been active in Europe so far, has also inked a partnership with US- based women’s health brand Phenology, Hologram Science‘s DTC brand, which will position Inne as a solution for women going through perimenopause.